Clinical implications of mucosal healing for the management of IBD. - Wikidata - awgldk - TriplyDB

Clinical implications of mucosal healing for the management of IBD.

Clinical implications of mucosal healing for the management of IBD.

http://www.wikidata.org/entity/Q37641754

about

Histologic scoring indices for evaluation of disease activity in ulcerative colitis Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin?Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases Indoleamine 2,3 dioxygenase in intestinal disease Clinical relevance of endoscopic assessment of inflammation in ulcerative colitis: Can endoscopic evaluation predict outcomes?Colon Capsule Endoscopy: Where Are We and Where Are We Going Nutritional Aspects of Gastrointestinal Wound Healing Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies Selective non-steroidal glucocorticoid receptor agonists attenuate inflammation but do not impair intestinal epithelial cell restitution in vitro Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members Histologic scoring indices for evaluation of disease activity in ulcerative colitis.Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis.Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn's disease, and clinical prognosis in inflammatory bowel disease.Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies.CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.Outcome predictors for intestinal Behçet's disease.Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy.The role and utility of faecal markers in inflammatory bowel disease.Alleviated mucosal and neuronal damage in a rat model of Crohn's disease.Colon capsule endoscopy: What we know and what we would like to know.Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.Use of confocal laser endomicroscopy to predict relapse of ulcerative colitis.An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease.Confocal laser endomicroscopy: a new gold standard for the assessment of mucosal healing in ulcerative colitis.Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health Mucosal healing in inflammatory bowel disease-a true paradigm of success?Comparing the efficacy of a web-assisted calprotectin-based treatment algorithm (IBD-live) with usual practices in teenagers with inflammatory bowel disease: study protocol for a randomized controlled trial Biomarkers in inflammatory bowel disease: current practices and recent advances.Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis The matricellular protein CCN1 promotes mucosal healing in murine colitis through IL-6.Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution Crucial steps in the natural history of inflammatory bowel disease.Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?Differential diagnosis of inflammatory bowel disease: what is the role of colonoscopy?EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS.Dietary Protein and Amino Acid Supplementation in Inflammatory Bowel Disease Course: What Impact on the Colonic Mucosa?

P2860

Q24194674-D4AF1883-5C6D-413B-A18D-B7046B580309 Q24658603-7E9C2426-70A3-4C4C-83F9-FB1B640B4CC9 Q26745712-D817B792-0DD2-49F8-96E4-16F699347A1A Q26765352-8A5D58DF-DC39-469B-A89D-7A0A7D449654 Q26994776-6097CEEA-9AF9-4B5B-9A38-0325519E5538 Q27008246-196E70F5-7BAA-4AD2-9F75-FA8B336C1D62 Q27025063-E832A589-A2CB-434C-8D62-8628AB879049 Q28072104-46EE7A44-30D1-49E9-A029-8329E144639C Q28073946-DEE4C826-AF48-4685-9416-4C2D348B1FB0 Q28078399-7AF560AB-9091-47CF-B98C-6B8CE5207FD6 Q28468381-4507F64D-0AF8-4A66-87DA-6F30D20FC012 Q28479065-DCF19513-878F-467A-8C6D-149EE1648F58 Q28542037-6152ADCB-1D8C-4857-B9B3-68DAE39DDBCC Q30234366-B3A30579-0A28-434A-B003-BE8F7E874DA5 Q33564132-AB16B72D-BF05-4053-AA61-9858B6C26E2A Q33667766-3CA0CC01-3B96-4D4B-A4D2-32076DD5EB32 Q33763285-CC025B85-B224-4556-B07E-99B7E674D55C Q33964256-2D866B1C-E9B7-45F7-B1E7-71B15AF273E9 Q34362079-F8F1BC6D-E352-4BD0-9A5A-3E0284086F50 Q34374449-6FB1B63E-438C-4C15-ABF2-6EF149380A73 Q34456258-F9661995-0286-4E80-9B5F-DDB2FE4705D7 Q34589792-79B1642D-B900-4B63-B623-465E93B205D6 Q34647472-6A4D1E63-4B26-4028-8A89-CD129BE26552 Q34648896-7DDC75B2-8216-43B8-AA4A-D7E95D5BF4EE Q34779205-85E0B30B-18A7-4C92-8366-4BEE055BCE11 Q35117320-F3A5A5CF-F5A0-46C3-8A3D-DA5EFDE57CF6 Q35586236-53BA9D72-D274-4E32-84D5-C657E02BD357 Q35591302-7DE5BCA2-6031-4303-8FA8-006A4EFD76B4 Q35633526-C3220F8A-2715-4021-9F0F-CB2D0E6F688D Q35749943-95EDF7BF-E358-4C47-8D84-76CC35B07DEF Q35801582-59FBD162-89F7-481F-8254-918F8A49C10B Q35840853-F89952E3-16DE-4799-ADEA-6645650FEF17 Q36075877-E264A747-17F3-464F-BDAC-4B86FAB58F9B Q36093753-A089E59F-65ED-4BC5-B90D-572A8D60AC6F Q36114510-36D61FB3-947F-4752-8B09-A2D3BCB94981 Q36144457-F9F50A73-0623-4DCA-8313-BBEA6BB0626A Q36193147-EE260FDD-95C0-479A-9DEB-536779AF062C Q36195354-EA16C81E-95E1-4B8E-914D-6C4F5FE32FCE Q36317757-7A152403-2B78-4E5F-B460-FA82000E5BC3 Q36320785-3A26F04E-6ECE-4939-8708-7C5F1A6A84FE

P2860

Clinical implications of mucosal healing for the management of IBD.

http://www.wikidata.org/entity/Q37641754

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Clinical implications of mucosal healing for the management of IBD.

@en

Clinical implications of mucosal healing for the management of IBD.

@nl

type

label

Clinical implications of mucosal healing for the management of IBD.

@en

Clinical implications of mucosal healing for the management of IBD.

@nl

prefLabel

Clinical implications of mucosal healing for the management of IBD.

@en

Clinical implications of mucosal healing for the management of IBD.

@nl

P1433

Q37641754-8AEB6FDC-9BEC-40D5-89BE-F67D97E7629B

P1476

Q37641754-B44CA080-5A05-4B95-8D77-46079ADB5ADF

P2093

Q37641754-16D4A5DD-40E6-417A-8D0C-E4933223CD50

Q37641754-F41147FE-8917-4D4C-A4AB-3186C84276D8

P2860

Q37641754-78010FA3-0448-486E-8C6C-FD8A1077EA1F

Q37641754-99BD65EA-4E0B-4EA5-8A40-9D47C0408F74

Q37641754-BDA680DD-569D-45DC-A6C9-4515227BEF72

Q37641754-F6BEA786-3965-4B37-A95B-F5CFCC958853

Q37641754-F962DC76-2FEA-4B6D-B52E-FB8C46D0AE1A

P2888

Q37641754-DE79DCF0-21E6-4035-96CC-37F3BE633D86

P304

Q37641754-65144587-9E40-4E5E-BA54-A81237655384

P31

Q37641754-9E9FA830-940A-47EB-894B-BBE698EC1EAA

P356

Q37641754-DFF4791A-9571-4A7A-BE1A-3141FF2E82BD

P407

Q37641754-CEDFA00F-CB9E-4B05-9216-282D7A95B416

P433

Q37641754-99F74EF5-24F9-4182-A23E-BF060DCC7D8B

P478

Q37641754-E02684A7-29DA-4B88-9E16-869EEC7D3BAB

P50

Q37641754-68FFFFEF-D66F-4885-9799-A6F685EA53A2

Q37641754-AAC765AF-AFF2-48AE-B989-ADB804CFA6B8

P577

Q37641754-92D8E38F-F48B-48BF-8156-2E74158D0178

P5875

Q37641754-B7306FEB-6473-41DE-8221-4CB081E8E2A5

P698

Q37641754-3669B102-7AA9-469F-9B54-84FCAFD9E751

P356

NRGASTRO.2009.203

P1433

Nature Reviews Gastroenterology & Hepatology

P1476

Clinical implications of mucosal healing for the management of IBD.

@en

P2093

Guillaume Pineton de Chambrun

http://www.w3.org/2001/XMLSchema#string

Marc Lémann

http://www.w3.org/2001/XMLSchema#string

P2860

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

A protective role of protease-activated receptor 1 in rat gastric mucosa

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease.

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

P2888

nrgastro.2009.203

P304

15-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRGASTRO.2009.203

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

Laurent Peyrin-Biroulet

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40042529

http://www.w3.org/2001/XMLSchema#string

P698

19949430

http://www.w3.org/2001/XMLSchema#string